feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

PSG vs Marseille live stream

trending

Leverkusen draw stops winning streak

trending

Olympiacos Panathinaikos Greek Super League

trending

Real Madrid vs Valencia live

trending

Juventus vs Lazio: Key Battles

trending

Yildiz extends Juventus contract

trending

Benfica aims to strengthen position

trending

Scotland seek Italy revenge

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Africa Launches HIV Injectable: Twice Yearly Protection

Africa Launches HIV Injectable: Twice Yearly Protection

1 Dec, 2025

•

Summary

  • New HIV injection offers over 99.9% protection, taken twice yearly.
  • South Africa, Eswatini, and Zambia are first to administer the drug.
  • US program provides millions of doses to high-burden countries.
Africa Launches HIV Injectable: Twice Yearly Protection

Africa is pioneering the rollout of lenacapavir, a groundbreaking injectable for HIV prevention administered only twice annually. South Africa, Eswatini, and Zambia commenced public administration of the drug, which has demonstrated over 99.9% efficacy in reducing HIV risk, akin to a potent vaccine. This launch signifies a major stride in regions grappling with the world's highest HIV prevalence.

The injectable's initial deployment is supported by initiatives like Unitaid and a US program that aims to provide two million doses to high-burden nations over three years. While South Africa is funding its own rollout, other countries like Eswatini and Zambia have received initial doses through the US initiative, bolstering national HIV response efforts and offering renewed hope.

Despite these advancements, concerns about drug pricing and accessibility persist, with critics highlighting the market price as prohibitive for many. The move to make generic versions available by 2027 offers future hope for broader access, as progress against HIV faces new challenges amid funding shifts.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The new HIV prevention injection was launched in South Africa on Monday.
Lenacapavir has been shown to reduce the risk of HIV transmission by more than 99.9 percent.
Lenacapavir is administered via injection twice a year.

Read more news on

Healthside-arrowSouth Africaside-arrow

You may also like

Zambia: Fisherman Dies After Elephant Escape, Crocodile Attack

6 Feb • 9 reads

article image

SiPhuthi Language Revival: A Resounding Success Story

20 Jan • 108 reads

article image

Amazigh Celebrate New Year 2976, Ahead by a Millennium

14 Jan • 146 reads

article image

South Africa Initiation Deaths: 41 Young Men Perish

31 Dec, 2025 • 208 reads

article image

Nissanka's 98 Powers Sri Lanka to Dominant Win

25 Nov, 2025 • 451 reads

article image